Chronic inflammatory demyelinating polyneuropathy cidp treatment market

Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers

Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in clinical trials. Furthermore, in March 2018, CSL Behring received U.S. FDA approval for Hizentra, which is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient treatment type, in which patients can infuse themselves. The approval was based on the phase III results of the clinical trial. These factors are expected to propel the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Moreover, there are several potential drugs in the pipeline for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). For instance, in January 2016, Shire plc, began clinical trials of HyQvia for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. HyQvia is a type of intravenous immunoglobulin therapy approved for the treatment of primary immunodeficiency and is currently in phase III of clinical trials for CIDP. Successful clinical trial completion and subsequent launch of these products is expected to boost global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Also, introduction of advanced technologies in diagnostic tools for chronic inflammatory demyelinating polyneuropathy (CIDP) disorder is expected to drive the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in July 2018, according to National Centre for Biotechnology Information (NCBI), multifocal visional evoked potential, a technique to diagnose CIDP is capable of detecting abnormalities in the optic nerve fiber, hence ensures higher accuracy in diagnosis. Therefore advancements in diagnostic tools of chronic inflammatory demyelinating polyneuropathy disorder are expected to support the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other organizations are expected to have an influence on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome & Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Restraints

Failure of the drugs in late stages of clinical trials has hampered the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, drugs such as Fingolimod (Gilenya, Novartis AG), and Acthar gel (Mallinckrodt Pharmaceuticals) indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) failed in the clinical trials in 2016, and 2018, respectively. These failures were associated with serious adverse events shown by these medications such as hypertension, extreme pain, fluid retention, alteration in glucose tolerance, and behavioral and mood changes.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Key Players

Some of the major players operating in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market include CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc., GeNeuro SA ,Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd. and Nihon Pharmaceutical Co. Ltd.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment Market Taxonomy

The global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market is segmented by treatment type, distribution channel and regions. 

By Treatment Type

• Intravenous immunoglobulin therapy
  • Privigen
  • Hizentra
  • Gamunex-C
  • Tegeline
  • Others
• Corticosteroids
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa